10-K/APeriod: FY2007

BIOGEN INC. Annual Report (Amendment), Year Ended Dec 31, 2007

Filed April 29, 2008For Securities:BIIB

Summary

This 10-K filing for Biogen Inc. (BIIB) as of April 29, 2008, primarily details the company's corporate governance, executive compensation, and security ownership. The report emphasizes the 'pay-for-performance' philosophy guiding executive compensation, with a focus on aligning executive incentives with company financial, strategic, and operational goals. Compensation is benchmarked against a peer group of biotechnology and pharmaceutical companies, with base salaries targeted at the median, and long-term incentives set between the median and 75th percentile. Key disclosures include the composition of the Board of Directors and its committees, highlighting the independence of most directors. The report details the compensation structure for named executive officers, including base salary, annual cash incentives, and long-term incentives (stock options and restricted stock units). It also outlines severance benefits for executives under various termination scenarios, including those related to corporate transactions or change in control. For investors, understanding the link between executive pay and company performance, as well as the terms of severance packages, is crucial for assessing management alignment and potential shareholder value.

Financial Highlights

31 data points
Beta

Revenue

$3.17B

89.4% Gross Margin

Net Income

$638.17M

20.1% Net Margin

EPS (Diluted)

$1.99

Cash & Equivalents

$659.66M

Free Cash Flow

$734.65M

Financial Statements
Beta
Revenue$3.17B
Cost of Revenue$335.19M
Gross Profit$2.84B
R&D Expenses$925.16M
SG&A Expenses$776.10M
Operating Expenses$2.39B
Operating Income$779.77M
Net Income$638.17M
EPS (Basic)$2.02
EPS (Diluted)$1.99
Shares Outstanding (Basic)315.84M
Shares Outstanding (Diluted)320.17M

Key Highlights

  • 1Biogen's executive compensation philosophy is strongly "pay-for-performance," aiming to attract and retain top talent through competitive compensation tied to financial, strategic, and operational goals.
  • 2The company benchmarks executive compensation against a peer group of biotechnology and pharmaceutical companies, targeting base salaries at the median and long-term incentives between the median and 75th percentile.
  • 3The Board of Directors is largely comprised of independent directors, with only the CEO and President of R&D not meeting the NASDAQ independence requirements.
  • 4Executive compensation includes base salary, annual cash incentives (with payouts ranging from 0% to 225% of target based on performance), and long-term incentives (stock options and restricted stock units).
  • 5Significant severance benefits are provided to executives, including potential payouts upon termination without cause or following a change in control, designed to ensure executive focus during uncertain times.
  • 6Director compensation includes annual retainers, meeting fees, and committee chair fees, with equity grants (stock options and restricted stock units) also provided, vesting over time.
  • 7The company outlines its equity compensation plans, including outstanding options and shares available for future issuance, and details security ownership by major beneficial owners, directors, and executive officers as of April 7, 2008.

Frequently Asked Questions

Biogen's executive compensation is determined by a "pay-for-performance" philosophy. It involves a Compensation and Management Development Committee that reviews base salaries, annual cash incentives, and long-term incentive grants. These decisions are influenced by company performance against financial, strategic, and operational goals, individual performance assessments, and competitive benchmarking against a peer group of similar biotechnology and pharmaceutical companies. The goal is to attract, retain, and motivate top talent by rewarding superior performance.

The long-term incentives offered to Biogen executives primarily consist of stock options and restricted stock units (RSUs). These awards are designed to align executive interests with those of stockholders, promote long-term retention, and encourage stock ownership. The total grant date value of annual merit and promotional awards is typically split evenly between stock options and RSUs. Some specific grants, like those to Dr. Pickett, are performance-based.

Biogen has established executive severance policies and employment agreements that provide benefits upon termination of employment or in the event of a corporate transaction or change in control. Depending on the circumstances (e.g., termination without cause, termination for good reason, or involuntary employment action following a change in control), executives may receive lump-sum severance payments, continuation of medical and dental benefits, outplacement services, and accelerated vesting of equity awards. These provisions are designed to retain key executives and provide them with security.

Biogen's Board of Directors has determined that most of its directors and nominees meet the independence requirements of The NASDAQ Stock Market. Only the CEO and the President of Research & Development are considered non-independent directors. The board also specifically evaluated potential independence concerns for directors with ties to other companies or transactions, ensuring that such relationships did not impair objectivity. Committees of the Board also consist solely of independent directors.